Incretin Atlas › Trials › OUTSTAND-1 (early T2D, monotherapy)
OUTSTAND-1 (early T2D, monotherapy)
HRS-7535 · t2d
Design
- Molecule(s)
- HRS-7535
- Population
- t2d
- Official title
- A Study of HRS-7535 Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequately Controlled With Diet and Exercise
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
- Phase
- 3
- Registry status
- completed · 2024-09 → 2025-11
- Participants
- 284
- Duration
- 32 weeks
- Registry
- NCT06672172
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| oral HRS-7535 90 mg | t2d china | 32 | 284 | — | — | −1.7 vs −0.1 | 6.9 vs 0.0 | — | — | — | — | — | congress |
| 30 mg | t2d china | 32 | 284 | — | — | −1.4 vs −0.2 | 1.4 vs 0.0 | — | — | — | — | — | congress |
| 60 mg | t2d china | 32 | 284 | — | — | −1.4 vs −0.2 | 2.9 vs 0.0 | — | — | — | — | — | congress |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Notes
- oral HRS-7535 90 mg: Efficacy estimand; treatment-policy −1.63 % vs −0.18 %
Verbatim quotes from the source (6)
- oral HRS-7535 90 mg · hba1c · abstract
reduced HbA1c from baseline by 1.40% (30 mg), 1.48% (60 mg), and 1.68% (90 mg) versus 0.06% with pbo
- oral HRS-7535 90 mg · ae_dc · abstract
mg), and 6.9% (90 mg) versus 0% with pbo in the 32-week period.
- 30 mg · hba1c · abstract
reduced HbA1c from baseline by 1.40% (30 mg), 1.48% (60 mg), and 1.68% (90 mg) versus 0.06% with pbo
- 30 mg · ae_dc · abstract
Discontinuation due to AEs occurred in 1.4% (30 mg), 2.9% (60
- 60 mg · hba1c · abstract
reduced HbA1c from baseline by 1.40% (30 mg), 1.48% (60 mg), and 1.68% (90 mg) versus 0.06% with pbo
- 60 mg · ae_dc · abstract
Discontinuation due to AEs occurred in 1.4% (30 mg), 2.9% (60
Primary sources
- Miao Yu et al. Oral small-molecule GLP-1 RA HRS-7535 as monotherapy in Chinese adults with early type 2 diabetes: the OUTSTAND-1 Phase 3 trial. Abstract LBA 39. EASD 2026 Annual Meeting; 2026 Sep 29–Oct 3; Milan. [Session: LBA SO 01 Eat, signal, treat: the rise of incretin therapies]
- EASD 2026 Annual Meeting; 2026 Sep 29–Oct 3; Milan. Abstract easd66720.
- Kailera / Hengrui. Kailera Therapeutics Announces Positive Topline Data from Two Hengrui Pharma Phase 3 Clinical Trials of HRS-7535/KAI-7535 (HARBOR-1, OUTSTAND-2) (GlobeNewswire via BioSpace) [press release]. 2026-07-07. Available from: https://www.biospace.com/press-releases/kailera-therapeutics-announces-positive-topline-data-from-two-hengrui-pharma-phase-3-clinical-trials-of-oral-small-molecule-glp-1-receptor-agonist-hrs-7535-kai-7535
- ClinicalTrials.gov NCT06672172
How to cite this page
Medical Adviser's Group. Incretin Atlas: OUTSTAND-1 (early T2D, monotherapy). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/outstand-1/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.